Quaker Chemical Reports $2.5M Net Loss for 2025 Driven by $88.8M EMEA Goodwill Impairment

summarizeSummary

Quaker Chemical reported a GAAP net loss of $2.5 million for 2025, primarily due to an $88.8 million goodwill impairment charge in its EMEA segment, despite a 3% increase in net sales driven by acquisitions.

check_boxKey Events

• Full Year 2025 Financial Performance

  Net sales increased 3% to $1.89 billion, but the company reported a GAAP net loss of $2.5 million, or $(0.14) per diluted share, compared to a net income of $116.6 million in 2024. Non-GAAP net income also decreased to $123.2 million from $133.5 million in the prior year.

• Significant Goodwill Impairment Charge

  An $88.8 million non-cash goodwill impairment charge was recorded in the second quarter of 2025, specifically impacting the EMEA reportable segment. This was driven by lower-than-projected financial performance due to soft end market conditions and an increased cost of capital.

• Strategic Acquisitions Drive Sales Growth

  The company completed several acquisitions in 2025, including Dipsol Chemicals Co., Ltd. (net purchase price $155.5 million), Natech, Ltd. ($6.5 million), and Chemical Solutions & Innovations (Pty) Ltd. ($3.9 million), which contributed approximately 4% to the net sales increase.

• Expanded Restructuring Program

  Additional actions under a global cost and optimization program were approved in 2025, expected to generate an extra $40 million in annualized cost savings by the end of 2026. Restructuring and related charges totaled $35.1 million in 2025.

auto_awesomeAnalysis

Quaker Chemical's 2025 annual report reveals a significant GAAP net loss, primarily due to an $88.8 million non-cash goodwill impairment charge in its EMEA segment. This impairment, attributed to soft market conditions and increased cost of capital, overshadows a 3% increase in net sales driven by recent acquisitions. While the company is actively pursuing growth through acquisitions and implementing a cost optimization program, the substantial impairment and decline in non-GAAP earnings signal underlying challenges in key markets. Investors should monitor the effectiveness of restructuring efforts and the performance of acquired businesses, particularly in the EMEA region, for signs of recovery and improved profitability.